financetom
Business
financetom
/
Business
/
Eton Pharmaceuticals Acquires Galzin to Expand Rare Disease Treatment Offerings
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Eton Pharmaceuticals Acquires Galzin to Expand Rare Disease Treatment Offerings
Jan 3, 2025 4:41 AM

07:19 AM EST, 01/03/2025 (MT Newswires) -- Eton Pharmaceuticals ( ETON ) said Friday that it acquired Galzin, an FDA-approved treatment for Wilson Disease.

The company plans to begin US commercialization in Q1 2025 and offer personalized support through its Eton Cares program, including a $0 co-pay for eligible patients.

Additionally, Eton said it acquired European rights to the product, which will continue to be marketed in Europe under the name Wilzin by a third-party distributor.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved